ASCO

Oncology

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

Oncology

ASCO 2026: A potential functional cure in endometrial cancer...

For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.

Oncology

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Are radiopharmaceuticals being systematically und...

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

ASCO 2026: A potential functional cure in endometrial cancer...

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

ASCO 2026: Powerful evidence for the microbiome in oncology,...

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

ASCO 2026: Are radiopharmaceuticals being systematically und...

Zymeworks cuts deal to buy Theravance for $929m in cash

Discover a new era of healthcare panel engagement: Grounded ...

ASCO

Editor's Picks